Back to Search
Start Over
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- Source :
- Haematologica. 102:e313-e316
- Publication Year :
- 2017
- Publisher :
- Ferrata Storti Foundation (Haematologica), 2017.
-
Abstract
- Complete remission (CR) rates for multiple myeloma (MM) have increased to 60% with current treatment approaches, including high dose melphalan-based autologous stem cell transplant (ASCT) and novel agents, and are associated with improved survival.[1][1]–[3][2] Despite this improvement, highly
- Subjects :
- Oncology
medicine.medical_specialty
Neoplasm, Residual
Time Factors
Risk Assessment
03 medical and health sciences
0302 clinical medicine
Internal medicine
Humans
Medicine
Online Only Articles
Multiple myeloma
Risk status
business.industry
Complete remission
High dose melphalan
Hematology
Prognosis
medicine.disease
Novel agents
030220 oncology & carcinogenesis
Immunology
Stem cell
Multiple Myeloma
business
030215 immunology
Subjects
Details
- ISSN :
- 15928721 and 03906078
- Volume :
- 102
- Database :
- OpenAIRE
- Journal :
- Haematologica
- Accession number :
- edsair.doi.dedup.....07cb71517158c03de8a3e08ac1a545d9